Form D · Biotechnology
Spark Therapeutics, Inc.
Philadelphia, PA · CIK 0001609351
Offering snapshot reported Jun 6, 2014 · SEC filing
- Reported sold
- $72.8M Offering amount: $72.8M
- Investors reported
- 28 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- May 23, 2014 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jun 6, 2014 | Initial | $72,800,000 | No comparison | 28 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-218710
Source: Form D, filed Jun 6, 2014. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Steven M. Altschuler | Director |
| Arthur Dantchik | Director |
| Lars Ekman, M.D. Ph.D. | Director |
| Joseph W. La Barge | Executive |
| Jeffrey D. Marrazzo | Director, Executive |
| Anand Mehra | Director |
| Elliott Sigal | Director |
| Rogerio Vivaldi | Director |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
3501 Civic Center Boulevard
Philadelphia, PA, 19104
Philadelphia, PA, 19104